Effect of Long-Term Oxybutynin Administration on c-Fos Expression in Spinal Neurons: Inhibition of Antimuscarinics on Bladder Afferents in Conscious Rats

Urology

Volumn 73, Issue 1, 2009, Pages 200-204

  Haga, Nobuhiro ^a   Aikawa, Ken ^a   Shishido, Keiichi ^a   Takahashi, Norio ^a   Yanagida, Tomohiko ^a   Yamaguchi, Osamu ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

OXYBUTYNIN; PROTEIN C FOS;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLADDER CAPACITY; CONTROLLED STUDY; CYSTOMETRY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MICTURITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SENSORY NERVE; SPINAL CORD; URODYNAMICS;

AFFERENT PATHWAYS; ANIMALS; CONSCIOUSNESS; FEMALE; MANDELIC ACIDS; MUSCARINIC ANTAGONISTS; NEURONS; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD; TIME FACTORS; URINARY BLADDER;

EID: 57849131184     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.04.038     Document Type: Article

References (14)

1. Andersson K.E. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 3 (2004) 46-53
2. Finney S.M., Andersson K.E., Gillespie J.I., et al. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: Motor or sensory actions?. BJU Int. 98 (2006) 503-507
3. Andersson K.E., and Yoshida M. Antimuscarinics and the overactive detrusor-Which is the main mechanism of action?. Eur Urol. 43 (2003) 1-5
4. Yokoyama O., Yusup A., Miwa Y., et al. Effects of tolterodine on an overactive bladder depend on suppression of C-fiber bladder afferent activity in rats. J Urol. 174 (2005) 2032-2036
5. Hedlund P., Streng T., Lee T., et al. Effects of tolterodine on afferent neurotransmission in normal and resiniferatoxin treated conscious rats. J Urol. 178 (2007) 326-331
6. De Laet K., De Wachter S., and Wyndaele J.J. Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: New insights into the working mechanism of antimuscarinics. Neurourol Urodyn. 25 (2006) 156-161
7. Birder L.A., and de Groat W.C. Induction of c-fos expression in spinal neurons by nociceptive and nonnociceptive stimulation of LUTS. Am J Physiol. 265 (1993) R326-R333
8. Birder L.A., and de Groat W.C. Increased c-fos expression in spinal neurons after irritation of the lower urinary tract in the rat. J Neurosci. 12 (1992) 4878-4889
9. Sawada H., Shinomura T., Kimata K., et al. Characterization of an anti-decorin monoclonal antibody, and its utility. J Biochem Tokyo 132 (2002) 997-1002
10. Noronha-Blob L., Lowe V.C., Peterson J.S., et al. The anticholinergic activity of agents indicated for urinary incontinence is an important property for effective control of bladder dysfunction. J Pharmacol Exp Ther. 251 (1989) 586-593
11. Yoshida M., Miyamae K., Iwashita H., et al. Management of detrusor dysfunction in the elderly: Changes in acetylcholine and adenosine triphosphate release during aging. Urology 63 (2004) 17-23
12. Yoshida M., Inadome A., Maeda Y., et al. Non-neuronal cholinergic system in human bladder urothelium. Urology 67 (2006) 425-430
13. Hawthorn M.H., Chapple C.R., Cock M., et al. Urothelium-derived inhibitory factor(s) influences on detrusor muscle contractility in vitro. Br J Pharmacol. 129 (2000) 416-419
14. Mukerji G., Yiangou Y., Grogono J., et al. Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol. 176 (2006) 367-373